172 related articles for article (PubMed ID: 28388903)
1. Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis.
Zhang H; Ge J; Hong H; Bi L; Sun Z
World J Surg Oncol; 2017 Apr; 15(1):75. PubMed ID: 28388903
[TBL] [Abstract][Full Text] [Related]
2. Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma.
Zhang Q; Lv LY; Li BJ; Zhang J; Wei F
Genet Mol Res; 2015 Sep; 14(3):11235-41. PubMed ID: 26400354
[TBL] [Abstract][Full Text] [Related]
3. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms of ERCC-1 and ERCC-2 are not prognostic markers in osteosarcoma patients with chemotherapy: A meta-analysis in Chinese population.
Liu D; Liu X
Medicine (Baltimore); 2018 Dec; 97(49):e13358. PubMed ID: 30544402
[TBL] [Abstract][Full Text] [Related]
5. Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma.
Cao ZH; Yin HP; Jiang N; Yu B
Genet Mol Res; 2015 Aug; 14(3):10145-51. PubMed ID: 26345951
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
Sun Y; Wu Y; Li W; Kong Z; Zou X
Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
[TBL] [Abstract][Full Text] [Related]
7. Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma.
Ji WP; He NB
Int J Clin Exp Pathol; 2015; 8(1):894-9. PubMed ID: 25755792
[TBL] [Abstract][Full Text] [Related]
8. Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients.
Hao T; Feng W; Zhang J; Sun YJ; Wang G
Asian Pac J Cancer Prev; 2012; 13(8):3821-4. PubMed ID: 23098477
[TBL] [Abstract][Full Text] [Related]
9. Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.
Salimzadeh H; Lindskog EB; Gustavsson B; Wettergren Y; Ljungman D
BMC Cancer; 2020 May; 20(1):409. PubMed ID: 32397974
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
Mo J; Luo M; Cui J; Zhou S
Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
[TBL] [Abstract][Full Text] [Related]
11. ERCC polymorphisms and risk of osteosarcoma: a meta-analysis.
Chen XJ; Tong ZC; Kang X; Wang ZC; Huang GL; Yang TM; Dong L
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6658-6666. PubMed ID: 30402838
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer.
Zhou J; Liu ZY; Li CB; Gao S; Ding LH; Wu XL; Wang ZY
Tumour Biol; 2015 Apr; 36(4):3017-23. PubMed ID: 25542228
[TBL] [Abstract][Full Text] [Related]
13. Association of ERCC gene polymorphism with osteosarcoma risk.
Wang G; Li J; Xu X; Gupta RK; Gao X
Afr Health Sci; 2020 Dec; 20(4):1840-1848. PubMed ID: 34394247
[TBL] [Abstract][Full Text] [Related]
14. Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.
Liu R; Zhao X; Liu X; Chen Z; Qiu L; Geng R; Guo W; He G; Yin J; Li J; Zhu X
Tumour Biol; 2016 Feb; 37(2):1753-62. PubMed ID: 26314858
[TBL] [Abstract][Full Text] [Related]
15. Association between common polymorphisms in ERCC gene and glioma risk: A meta-analysis of 15 studies.
Qian T; Zhang B; Qian C; He Y; Li Y
Medicine (Baltimore); 2017 May; 96(20):e6832. PubMed ID: 28514298
[TBL] [Abstract][Full Text] [Related]
16. ERCC1 and ERCC2 variants predict survival in gastric cancer patients.
Li Y; Liu Z; Liu H; Wang LE; Tan D; Ajani JA; Wei QY
PLoS One; 2013; 8(9):e71994. PubMed ID: 24023723
[TBL] [Abstract][Full Text] [Related]
17. Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors.
Yang LM; Li XH; Bao CF
Asian Pac J Cancer Prev; 2012; 13(11):5883-6. PubMed ID: 23317281
[TBL] [Abstract][Full Text] [Related]
18. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
[TBL] [Abstract][Full Text] [Related]
19. ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.
Lu X; Xiao S; Jin C; van der Straaten T; Li X
J Clin Lab Anal; 2012 Jan; 26(1):10-5. PubMed ID: 24833529
[TBL] [Abstract][Full Text] [Related]
20. Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma.
Wang MJ; Zhu Y; Guo XJ; Tian ZZ
Genet Mol Res; 2015 Sep; 14(3):11652-7. PubMed ID: 26436406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
